In Brief: OncorMed
This article was originally published in The Gray Sheet
Executive Summary
OncorMed: Will begin offering BRCA2 genetic testing Aug. 1 for susceptibility to breast and ovarian cancer, the Gaithersburg, Maryland firm announces. Pricing for BRCA2 testing will be comparable to OncorMed's current BRCA1 gene test: $420 for "stage 1" testing, the portion of the gene most likely to carry a mutation; and $775 for "stage 2" testing. Combined testing for both genes is $500 and $800 for stage 1 and stage 2, respectively. As with BRCA1 testing, BRCA2 testing will be available to physicians and medical centers under protocols developed by in-house institutional review boards or under an OncorMed-developed protocol ("The Gray Sheet" Jan. 15, p. 4)...